Semaglutide peptide dosing: how the titration schedule works in practice

You've heard the pen is 2.4 mg, so why does it start at 0.25?

It's a question our prescribers hear regularly, and the short answer is: that first dose isn't there to shift the scales. It's there to introduce the peptide to your system without overwhelming it. Semaglutide slows gastric emptying alongside its appetite effects, and when that mechanism kicks in suddenly at a high dose, nausea and vomiting follow. The 0.25 mg starting point gives the gut four weeks to adjust before anything changes.

For the injectable Wegovy, the pathway runs: 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg as the standard maintenance dose. The MHRA approved a 7.2 mg maintenance dose in January 2026, with a dedicated single-dose pen following in April 2026 for adults with a BMI of 30 or above. That higher ceiling narrows the gap with tirzepatide's trial results considerably, trials reported around 20.7% average weight loss at 7.2 mg over 72 weeks. You can read more about the full Wegovy options on our Wegovy overview page.

The oral tablet, approved by the MHRA on 11 June 2026 as the UK's first licensed oral GLP-1 for weight management, runs a different ladder entirely: 1.5 mg daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose. The mechanism at each step is the same, tolerance before efficacy. A common misconception is that the oral dose must be much higher because it's less potent; actually, the difference reflects the absorption challenge of getting a peptide across the gut wall, which is why it's taken on an empty stomach with a small amount of plain water and nothing else for at least 30 minutes. That rule matters, skipping it meaningfully reduces how much semaglutide reaches the bloodstream.

What the peptide is actually doing at each dose level

Semaglutide binds to GLP-1 receptors in the gut, pancreas and brain. At the gut level it slows how quickly food leaves the stomach, which prolongs the feeling of fullness after eating. At the brain level it acts on appetite-regulating centres, reducing the drive to eat rather than just making food harder to enjoy. The result is that most people eat less without a constant battle against hunger, though the degree varies between individuals.

The dose-response relationship is real: the STEP 1 trial, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% at the 2.4 mg maintenance dose over 68 weeks. That figure climbs with the 7.2 mg dose. At lower doses during titration, weight loss tends to be modest, which can feel discouraging at weeks four or eight, but if you want to understand exactly how each step is structured, our guide to semaglutide dosing walks through the full schedule in detail. The therapeutic work happens at maintenance.

Side effects are most common after starting or stepping up. Nausea, loose stools, constipation, reflux and fatigue are the ones patients most often describe, and they tend to ease within a week or two once the body adapts. If they don't settle, or if someone experiences severe stomach pain that spreads to the back, they should seek medical attention promptly, the NHS semaglutide medicines page covers what to watch for in plain language. Dose escalation can be paused at any step if tolerability is a problem; that decision belongs to the prescriber.

Who can be prescribed semaglutide for weight management in the UK

The licensed indication for Wegovy covers adults with a BMI of 30 or above, or those with a BMI of 27 to 29.9 who also have at least one weight-related health condition, high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea, among others. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Those who are pregnant, breastfeeding or trying to conceive are not suitable candidates, and the medicine is not licensed for under-18s.

On the NHS, access to Wegovy is through specialist weight management services under NICE guidance (TA875), which includes a two-year treatment limit and multidisciplinary support, and waiting lists in many areas remain long. For people who don't meet the current NHS criteria or prefer not to wait, a private prescription through a regulated online pharmacy is the alternative. If you're weighing up costs, our guide to Wegovy pricing sets out what a legitimate private prescription typically involves and what to watch out for.

Eligibility isn't decided by a BMI number alone. A GPhC-registered prescriber reviews the full clinical picture, including current medications, medical history and any contraindications, before any prescription is issued. It is worth noting that semaglutide is a prescription-only medicine, no legitimate route exists that bypasses a clinical assessment.

Dosing after transfer or during a dose increase: what evidence is needed

People transferring from another provider, or requesting a dose increase, sometimes assume the process restarts from scratch. It doesn't have to. A prescriber reviewing a transfer patient will typically want to see evidence of current treatment (the dose, how long you've been on it and how you're tolerating it) so that continuity is maintained safely. At nume, transfers and dose increases go through clinical review before anything changes; a real prescriber, not an automated system, makes that call.

For patients established on the 2.4 mg weekly injection who are moving to the oral tablet, the MHRA's approval notes that a direct switch to the 25 mg tablet dose is possible, subject to prescriber assessment. It's a genuinely different product (different absorption route, different storage (no refrigeration needed), different morning routine) so clinical review before switching is the sensible step rather than an administrative one.

If you have questions about your own situation, the nume FAQs cover common queries, or you can get in touch via our contact page. For a full clinical picture of how semaglutide works as a peptide, our page on semaglutide peptides explains the science behind how this class of molecules behaves in the body, and if you've come across different names for the compound and want to understand which refers to what, our explainer on the semaglutide peptide name clarifies the terminology. The semaglutide peptide overview is a good companion read. When you're ready to explore whether treatment is right for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.